Rolapitant (Varuby®) for the prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults

The National Health Care Institute has carried out an assessment of the medicinal product rolapitant (Varuby®).
The GVS report concludes that, based on the criteria for interchangeability, rolapitant is interchangeable with aprepitant (Emend®). Aprepitant has already been included in the GVS on List 1B. Based on the above, rolapitant (Varuby®) can be placed on List 1A in a new cluster together with aprepitant. 

This report is a summary of recommendations by the National Health Care Institute. The original text is in Dutch.